DMAC Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -1.12%, SMA50 -1.02%, SMA200 28.95%). The stock’s 14-day RSI is 47.68 (neutral), while the ATR of 0.49 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -21.01% below its high and over 157.99% above its low. Average 10-day trading volume of 156.28 thousand shares is below the 3-month average of 189.26 thousand, indicating normal recent market interest.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) closed at $6.55 USD, gaining $0.08 (1.24%) from the previous close of $6.47. The stock is currently mid-range between its 52-week high and low $5.25 and $10.42. With a market capitalization of about $352.94 million, DiaMedica Therapeutics Inc. is classified as a small-cap and shows market-like volatility (beta ~0.97). Key stats such as the average daily volume over the past year has been around 190.43 thousand shares, in line with its 52-week average. Headquartered in Minneapolis, MN, DiaMedica Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dietrich John Pauls, the company employs approximately 35 people and listed since August 03, 2012. DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders.

DiaMedica Therapeutics Inc. generated EPS of -$0.72 over the past year. Five-year average earnings growth is 7.39%. Wall Street analysts project EPS growth of -13.62% annually over the next five years. The latest quarter delivered EPS of -$0.19. The next quarter is forecast at -$0.18. Next year's EPS is expected at -$10.50. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $25.00. The high target offers 286.4% upside. The low target suggests 286.4% downside. The mean target is $25.00. This offers 286.4% upside. DiaMedica Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by -5.43%. The prior quarter beat by -5.43%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 12, 2025.

DiaMedica Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.33. This means the shares are trading above this model’s fair value.

DiaMedica Therapeutics Inc. has 53.93 million shares outstanding. The public float is 25.30 million shares, elevated short interest at 14.38% of float. This equals 5.20 million shares. The short ratio is 23.74 days. Institutional investors hold 52.49% of the float. Insiders own 27.74%. STAHLBERG JAN holds 8.83 million shares, Von Koch Thomas has 8.38 million shares and JACINTO RICHARD II has 4.96 million shares.

DiaMedica Therapeutics Inc. trades at a P/E ratio of -9.08, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 9.19 trading at moderately above to book value. The P/FCF stands at -11.15, also below market averages.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) shares are flat -6.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows DiaMedica Therapeutics Inc. trading at a premium to the broader market with a P/E of -9.08. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $12.70, suggesting 96.29% upside. Our AI forecast model points to short-term weakness (-1.24% over two weeks), a medium-term rise (23.18% over three months), and a longer-term gain (148.07% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that DiaMedica Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.24%, with price expected at $6.39 by September 25, 2026, within a range of $6.22 to $6.55 3-Month Outlook: Projected rise of 23.18%, reaching $7.97 by December 10, 2026, with a range of $7.85 to $8.11. 1-Year Outlook: Projected gain of 148.07%, with price at $16.05 by September 10, 2027, within a range of $10.79 to $21.70.